Mizuho Securities analyst Ann Hynes has reiterated their bullish stance on BTSG stock, giving a Buy rating on March 10.
Ann Hynes has given her Buy rating due to a combination of factors that highlight BrightSpring Health Services, Inc.’s strong growth prospects. The company has demonstrated robust revenue growth, particularly in its specialty and infusion business, which slightly exceeded market expectations. Additionally, the pharmacy solutions segment showed significant improvement in both revenue and prescription volume, contributing to the overall positive outlook.
Furthermore, BrightSpring’s strategic focus on expanding its market presence through limited distribution drug awards and the increasing adoption of biosimilars and oncology specialty therapies supports its growth trajectory. The company’s updated guidance for 2025, which includes an increase in revenue and adjusted EBITDA estimates, reflects strong execution and a promising earnings outlook. Ann Hynes maintains a price target of $22, based on a favorable valuation compared to industry peers, reinforcing her confidence in the company’s future performance.
In another report released on March 10, Wells Fargo also maintained a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BTSG in relation to earlier this year.